Roche prices personalized cancer treatment at about US$204,560 annually

Singapore News News

Roche prices personalized cancer treatment at about US$204,560 annually
Singapore Latest News,Singapore Headlines
  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 66%

Roche Holding AG priced at about US$204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic ...

REUTERS: Roche Holding AG priced at about US$204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

The treatment was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumors, which show rare genetic anomalies called NTRK fusions.The treatment also won approval to treat adults with non-small cell lung cancer, whose tumors show genetic mutations called ROS1 fusions.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

ChannelNewsAsia /  🏆 6. in SG

Singapore Latest News, Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Roche's personalized cancer treatment wins FDA approvalRoche's personalized cancer treatment wins FDA approvalThe U.S. Food and Drug Administration approved Roche Holding AG's personalized cancer treatment, the agency said on Thursday.
Read more »

FDA approves Celgene's bone marrow cancer treatmentFDA approves Celgene's bone marrow cancer treatmentREUTERS: The U.S. Food and Drug Administration said on Friday it had approved Celgene Corp's treatment, Inrebic, for certain forms of bone marrow ...
Read more »

US FDA approves TB Alliance's treatment for drug-resistant tuberculosisUS FDA approves TB Alliance's treatment for drug-resistant tuberculosisThe U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination ...
Read more »

Disparities in access to best stroke treatmentDisparities in access to best stroke treatment(Reuters Health) - Less than 10per cent of U.S. stroke patients get a treatment that evidence shows is most effective for a certain type of stroke ...
Read more »

Kraft, Mondelez to pay US$16 million in wheat price manipulation caseKraft, Mondelez to pay US$16 million in wheat price manipulation caseThe U.S. Commodity Futures Trading Commission (CFTC) said on Thursday Kraft Heinz Co and Mondelez International Inc will pay US$16 million in ...
Read more »

US import prices rebound, but trend remains subduedUS import prices rebound, but trend remains subduedUS import prices unexpectedly rose in July, but the underlying trend continued to be weak, pointing to subdued imported inflation pressures.
Read more »



Render Time: 2025-03-12 14:45:06